Financial Performance - Revenue for the period was approximately HKD 85,706,000, an increase of about 2.40% compared to HKD 83,695,000 in the same period last year[5] - The company reported a loss attributable to owners of approximately HKD 712,000, compared to a profit of HKD 1,256,000 in the previous year[5] - Basic and diluted loss per share was approximately HKD 0.127, compared to a profit of HKD 0.22 per share in the previous year[7] - Gross profit for the period was HKD 25,774,000, down from HKD 26,433,000 in the previous year[6] - The company reported a total comprehensive income of HKD 152,000, significantly lower than HKD 2,791,000 in the previous year[6] - Total comprehensive income for the period ended September 30, 2025, was HKD 289,000, a significant decrease from HKD 2,726,000 in the previous period[17] - The group recorded a loss attributable to the owners of approximately HKD 712,000, compared to a profit of HKD 1,256,000 in the previous year[61] Cash Flow and Liquidity - Total cash and cash equivalents as of September 30, 2025, were approximately HKD 18,918,000, down from HKD 24,083,000 as of March 31, 2025[5] - As of September 30, 2025, the net cash generated from operating activities was HKD 3,126,000, compared to HKD 11,159,000 for the same period in 2024, representing a decrease of approximately 72%[17] - The net cash used in financing activities was HKD 8,444,000 for the six months ended September 30, 2025, compared to a net cash inflow of HKD 1,630,000 in 2024[17] - The cash and cash equivalents decreased by HKD 5,317,000 during the six months ended September 30, 2025, compared to an increase of HKD 12,815,000 in the same period of 2024[17] Assets and Liabilities - Total assets amounted to HKD 108,159,000 as of September 30, 2025, compared to HKD 106,822,000 as of March 31, 2025[8] - Current liabilities increased to HKD 30,599,000 from HKD 29,002,000 in the previous period[9] - Non-current assets decreased to HKD 48,082,000 from HKD 50,208,000[8] - Total liabilities as of September 30, 2025, were HKD 39,374,000, with HKD 33,404,000 classified liabilities and HKD 5,970,000 unallocated corporate liabilities[30] Revenue Breakdown - Revenue from external customers for the six months ended September 30, 2025, was HKD 85,706,000, with HKD 25,617,000 from pharmaceutical wholesale and distribution, and HKD 60,089,000 from hemodialysis treatment and consulting services[27] - Revenue from the wholesale business was approximately HKD 25,617,000, a decrease of about 5.93% from HKD 27,232,000 in the previous year, attributed to reduced demand from hospitals and clinics[48][53] - Revenue from the dialysis business was approximately HKD 60,089,000, an increase of about 6.42% from HKD 56,463,000 in the previous year, driven by an increase in the number of patients treated[49][54] Shareholder Information - As of September 30, 2025, Mr. Wang holds a total equity interest of 30.12% in the company, including 156,862,198 shares and 2,500,000 options[77] - Major shareholder 威揚 holds 156,862,198 shares, representing approximately 28.00% of the total issued shares as of September 30, 2025[79] - 泓港財務有限公司, Expert Wealth Investments Limited, and 吳國輝 have released their security interest in the 156,862,198 shares held by 威揚[80] Stock Options and Share Schemes - A total of 80,793,054 stock options have been granted under the 2013 stock option plan, representing approximately 14.42% of the total issued shares[83] - The 2023 stock option plan allows for the issuance of 56,022,213 stock options, which is about 10.00% of the total issued shares[84] - The exercise price for stock options ranges from 0.094 to 0.668 per share, with various exercise periods extending to 2033[83] - The 2023 Share Option Scheme was adopted on September 15, 2023, to attract and retain top talent and provide additional incentives to eligible participants[88] Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the group's unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[101] - The Compensation Committee was established on September 24, 2013, and includes one executive director and three independent non-executive directors[102] - The main responsibilities of the Nomination and Corporate Governance Committee include reviewing the board's structure and recommending changes, as well as maintaining effective corporate governance and internal control systems[104] Compliance and Risk Management - The company is actively monitoring compliance with external regulatory requirements and assessing their impact on existing operations[67] - Following a recent compliance issue, the company is implementing corrective measures to ensure adherence to applicable laws and regulations[74] - The company has not engaged in any major acquisitions or disposals during the reporting period[71] Employee Information - As of September 30, 2025, the company employed 177 full-time employees, with total employee costs amounting to approximately HKD 14,424,000, an increase from HKD 13,360,000 in 2024[73]
万嘉集团(00401) - 2026 - 中期财报